Amgen intends to price five-, seven- and 10-year senior notes and 4.4% notes due 2045

By Lisa Kerner

Charlotte, N.C., Aug. 10 – Amgen Inc. intends to price five-, seven- and 10-year senior notes (Baa1) and an add-on to its 4.4% senior notes due 2045, according to a 424B3 filed with the Securities and Exchange Commission.

Joint bookrunners are Goldman Sachs & Co., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and HSBC Securities (USA) Inc.

Amgen originally sold $1.25 billion of the 4.4% notes due 2045 on April 28, 2015 at 175 basis points over Treasuries.

Proceeds will be used to repay debt, including borrowings under the company’s term loan credit agreement, to repurchase common stock and for general corporate purposes.

Amgen is a Thousand Oaks, Calif., manufacturer and marketer of human therapeutics based upon advances in cellular and molecular biology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.